Skip to main content
CRS 2026 Annual Meeting & Exposition Main banner

Nanomedicine and Nanoscale Delivery (Focus Group – NND)

Toward Precision Protein Degradation: Targeted Delivery of Molecular Glues in Multiple Myeloma

Charline Keller – PhD Candidate, Laboratoire de Spectrométrie de Masse BioOrganique, Institut Pluridisciplinaire Hubert Curien (UMR 7178), CNRS, Université de Strasbourg; Mainak Banerjee – Research Scientist, Nanomedicine Laboratory, Institut Strauss; Christine Carapito – Director, Laboratoire de Spectrométrie de Masse BioOrganique, Institut Pluridisciplinaire Hubert Curien (UMR 7178), CNRS Université de Strasbourg; Alexandre Detappe – Director, Nanomedicine Laboratory, Institut Strauss
Introduction:

Multiple myeloma (MM) is a hematological cancer characterized by repeated relapses and drug resistances. Molecular glues (MGs) represent a promising strategy that selectively degrade disease-associated proteins, but poor solubility and limited tumor selectivity remain critical barriers to their clinical translation. We investigated whether combining a newly developed GSPT1 molecular glue with a targeted liposomal delivery system could improve drug delivery and precision protein degradation at the single cell level.

Learning Objectives:

  • Upon completion, participant will be able to understand key principles, potential, and limits of molecular glues.
  • Upon completion, participant will be able to apply new analytical tools in nanomedicine.
  • Upon completion, participant will be able to explore new nanocarrier design opportunities.